Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tiny taxanes

How NanOlogy's particle production technology created submicron chemotherapy

NanOlogy LLC is using submicron particle production technology to rework chemotherapeutics into stable nano-sized particles and deliver them directly to disease sites. The technology could increase the efficacy and reduce the side effects associated with systemic administration.

Formed in 2015, NanOlogy pooled expertise from DFB Pharmaceuticals LLC, CritiTech Inc. and US Biotest Inc. and then licensed the exclusive rights for CritiTech’s

Read the full 616 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE